Non-Hodgkin Lymphoma After Starting New HIV Treatments
Author Information
Author(s): Gregory D Huhn, Sheila Badri, Sonia Vibhakar, Frank Tverdek, Christopher Crank, Ronald Lubelchek, Blake Max, David Simon, Beverly Sha, Oluwatoyin Adeyemi, Patricia Herrera, Allan Tenorio, Harold Kessler, David Barker
Primary Institution: The Ruth M. Rothstein CORE Center
Hypothesis
What immunologic and virologic factors are associated with the rapid development of non-Hodgkin lymphoma (NHL) in HIV-infected patients after starting newer-class antiretroviral therapy?
Conclusion
The study found a surprisingly high rate of NHL among HIV patients who had a good virologic response to newer antiretrovirals, suggesting that immune reconstitution may play a role in NHL development.
Supporting Evidence
- Five cases of NHL were identified among 78 patients, indicating a mean incidence of 64.1 per 1000 patient-years.
- The median time from starting new antiretrovirals to NHL symptom onset was 5 weeks.
- At week 12, NHL cases showed a mean viral load reduction of 2.79 compared to 1.94 in controls.
Takeaway
Some HIV patients developed a type of cancer called non-Hodgkin lymphoma shortly after starting new medications, even though these medications usually help them get better.
Methodology
The study analyzed cases of NHL among HIV-infected patients who started newer-class antiretrovirals, comparing their immunologic and virologic data to controls without NHL.
Potential Biases
The study may have missed NHL cases that were present before starting treatment, and the small sample size could introduce bias.
Limitations
The observational nature of the study may not account for all risk factors for NHL, and the small sample size limits the precision of the analysis.
Participant Demographics
Median age of participants was 46 years, with 80% of NHL cases being male.
Statistical Information
P-Value
0.045
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website